New Science Ventures
New Science Ventures (NSV) is a Connecticut- and London-based venture capital firm that invests in early- and late-stage companies that apply novel scientific approaches across Life Sciences and Information Technology. NSV provides capital, board-level guidance, and access to external networks to support company formation, financing, commercialization and exits.
Industries
Nr. of Employees
small (1-50)
New Science Ventures
Portfolio
Developing autologous tissue regeneration products (NVD003, NVDX3). Reported Phase 1/2 five-year follow-up results, obtained RMAT designation for NVD003, and announced pediatric implantations in Phase 1b/2a trials and Series B financings.
#Regenerative medicine / clinical-stage biotechnology
Announced collaborations with Duke University to study cell-free RNA in polytrauma and advancing clinical programs including long-COVID research.
#Biotherapeutics / cell-free nucleic acid therapeutics
Develops oral small-molecule therapies (TYK2 inhibitors, NLRP3 inhibitors). Reported multiple clinical milestones including Phase 1 and Phase 2 trials and raised multiple financing rounds.
#Clinical-stage biopharmaceuticals (autoimmune/inflammatory disease)
NSV is a founding investor; company announced a merger to list on Nasdaq and commercial shipments of Speedster7t FPGA devices.
#Semiconductor / high-performance FPGAs
Develops radio-frequency thruster plasma propulsion systems for satellites. NSV led a $26M Series B financing to support commercialization and scaling.
#Space propulsion / aerospace
Raised $56M Series B with NSV as lead investor; developing on-demand personal rapid transit solutions.
#Transportation / Personal Rapid Transit (PRT)
Developing autologous tissue regeneration products (NVD003, NVDX3). Reported Phase 1/2 five-year follow-up results, obtained RMAT designation for NVD003, and announced pediatric implantations in Phase 1b/2a trials and Series B financings.
#Regenerative medicine / clinical-stage biotechnology
Announced collaborations with Duke University to study cell-free RNA in polytrauma and advancing clinical programs including long-COVID research.
#Biotherapeutics / cell-free nucleic acid therapeutics
Develops oral small-molecule therapies (TYK2 inhibitors, NLRP3 inhibitors). Reported multiple clinical milestones including Phase 1 and Phase 2 trials and raised multiple financing rounds.
#Clinical-stage biopharmaceuticals (autoimmune/inflammatory disease)
NSV is a founding investor; company announced a merger to list on Nasdaq and commercial shipments of Speedster7t FPGA devices.
#Semiconductor / high-performance FPGAs
Develops radio-frequency thruster plasma propulsion systems for satellites. NSV led a $26M Series B financing to support commercialization and scaling.
#Space propulsion / aerospace
Raised $56M Series B with NSV as lead investor; developing on-demand personal rapid transit solutions.
#Transportation / Personal Rapid Transit (PRT)